Similarly, increases in MPO were reported in the SOD1G93A animal model of ALS [47, 48], another neurodegenerative disease in which microglia activation plays a critical pathogenic role [49], thus suggesting that verdiperstat could exert a therapeutic effect in ALS and providing the groundwork for assessing verdiperstat in a clinical trial for ALS (NCT04436510 or Regimen B in the Healey ALS Platform Trial in ALS). This evidence concerns the gene MPO and neurodegenerative disease.